Oramed Pharmaceuticals Inc. — Director's Dealing 2026

Jan 29, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2026-01-22

Reporting Person: Kidron Miriam (Director, Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-22	Common Stock	M	19000	—	Acquired	1448664	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-22	Performance Stock Units	$	M	19000	Disposed		Common Stock (19000)	Direct

Footnotes

F1: Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.

F2: Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.